US FDA grants Fasenra ODD for EGPA
26 November 2018 07:00 GMT US FDA grants Fasenra Orphan Drug Designationfor Eosinophilic Granulomatosis with Polyangiitis AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Fasenra (benralizumab) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA). EGPA is a rare autoimmune disease that can cause damage to multiple organs and tissues.1 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000